Biotage AB
STO:BIOT

Watchlist Manager
Biotage AB Logo
Biotage AB
STO:BIOT
Watchlist
Price: 160.7 SEK 0.63% Market Closed
Market Cap: 12.9B SEK
Have any thoughts about
Biotage AB?
Write Note

Biotage AB
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biotage AB
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Biotage AB
STO:BIOT
Total Equity
kr3.8B
CAGR 3-Years
52%
CAGR 5-Years
34%
CAGR 10-Years
23%
AddLife AB
STO:ALIF B
Total Equity
kr5B
CAGR 3-Years
38%
CAGR 5-Years
40%
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Total Equity
kr3.1B
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genovis AB
STO:GENO
Total Equity
kr207.6m
CAGR 3-Years
32%
CAGR 5-Years
48%
CAGR 10-Years
22%
MedCap AB (publ)
STO:MCAP
Total Equity
kr1.2B
CAGR 3-Years
23%
CAGR 5-Years
30%
CAGR 10-Years
17%
M
Magle Chemoswed Holding AB
STO:MAGLE
Total Equity
kr158.2m
CAGR 3-Years
11%
CAGR 5-Years
26%
CAGR 10-Years
N/A
No Stocks Found

Biotage AB
Glance View

Market Cap
12.9B SEK
Industry
Life Sciences Tools & Services

Biotage AB, a Swedish life sciences company, has carved a significant niche within the analytical and organic chemistry sectors since its inception. The company's core operations revolve around the development of innovative solutions designed to facilitate drug discovery, genetic research, and infection diagnostics. By offering products that simplify and accelerate chemical synthesis, Biotage has become essential to the pharmaceutical and biotechnology industries. The company's product lineup includes automated sample preparation systems, flash chromatography instruments, and peptide synthesis solutions. These tools are indispensable for researchers and lab technicians, making complex laboratory processes more efficient and less time-consuming. Financially, Biotage generates revenue through the sale and distribution of its cutting-edge laboratory instruments and their accompanying consumables. In addition to equipment sales, the company also engages in service contracts and after-sales support, which provides a steady stream of recurring income. This dual model of one-time equipment purchases combined with ongoing service and supply needs ensures a stable revenue base. Biotage stays competitive by continually innovating and refining its technology, ensuring its solutions remain indispensable to scientists addressing critical challenges in medicine, environmental testing, and other fields that demand highly precise chemical processes.

BIOT Intrinsic Value
181.41 SEK
Undervaluation 11%
Intrinsic Value
Price

See Also

What is Biotage AB's Total Equity?
Total Equity
3.8B SEK

Based on the financial report for Sep 30, 2024, Biotage AB's Total Equity amounts to 3.8B SEK.

What is Biotage AB's Total Equity growth rate?
Total Equity CAGR 10Y
23%

Over the last year, the Total Equity growth was 3%. The average annual Total Equity growth rates for Biotage AB have been 52% over the past three years , 34% over the past five years , and 23% over the past ten years .

Back to Top